Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET)


Indications

Diagnosis/Staging of Langerhans Cell Histiocytosis (LCH) (see Langerhans Cell Histiocytosis, [[Langerhans Cell Histiocytosis]])

Diagnosis/Staging of Neuroendocrine Tumors

Diagnosis/Staging of Non-Small Cell and Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]])

Diagnosis/Staging of Pleural Mesothelioma (see Pleural Mesothelioma, [[Pleural Mesothelioma]])


Technique

Positron Emission Tomography (PET) Uses 18F-Fluorodeoxyglucose (FDG) as a Tracer

Spatial Resolution of Positron Emission Tomography (PET)

Clinical Efficacy of Positron Emission Tomography (PET)

Positron Emission Tomography (PET) Determination of the T Factor in Lung Cancer Staging (Tumor Size)

Positron Emission Tomography (PET) Determination of the N Factor in Lung Cancer Staging (Staging of Mediastinal Lymph Nodes)

Positron Emission Tomography (PET) For Determination of the M Factor in Lung Cancer Staging (Staging of Metastatic Disease)

Clinical Efficacy of Integrated Positron Emission Tomography-Computed Tomography (PET-CT) (in a Single Gantry)

PET-CT For Determination of the T Factor in Lung Cancer Staging (Tumor Size)

PET-CT For Determination of the N Factor in Lung Cancer Staging (Staging of Mediastinal Lymph Nodes)

PET-CT For Determination of the M Factor in Lung Cancer Staging (Staging of Metastatic Disease)


Etiology of False-Negative Positron Emission Tomography (PET) Scan

Lesion-Dependent

Technique-Dependent


Etiology of False-Positive Positron Emission Tomography (PET) Scan

Infectious/Inflammatory Lesions

Iatrogenic Etiologies

Benign Mass Lesions

Focal Physiologic FDG Uptake


References